Invivyd Presents Data on Pemgarda’s Efficacy Against COVID-19 Variants at IDWeek

Immunocompromised people are the most at risk to severe issues with At IDWeek in Las Angeles, California, Invivyd (“In VIVID”), the maker of PEMGARDA, a COVID-19 prevention option with FDA Emergency Use Authorization, presented data demonstrating the efficacy of Pemgarda against COVID-19 strains dating back to the Omicron strain for immunocompromised people.

To learn more, Infection Control Today^® (ICT^®) caught up with Robert Allen, PhD, Invivyd's chief science officer. He explained the main takeaway from his presentation and discussed the 2 posters Invivyd presented at IDWeek.

“The main thing to give them data, empirical underpinnings, so that they can understand that this antibody, which is as an [emergency use authorization] for administration to immunocompromised individuals, right that this antibody has profound efficacy, during the course of canopy, has demonstrated efficacy during times when we saw when we look at the variants that were prevalent at the different time points in those 6 months…[many] different variants that have sort of evolved [to] continue to be susceptible to Pemgarda,” Allen said.

“The takeaway needs to be that when people think about recommending this for use in the context of transplant or individuals [who] are being administered compounds that lead to an immunocompromised state in the context of treatment for other diseases that they might be suffering from, those immunocompromised individuals could benefit from this in the eyes of their positions, and that conversation can be fueled by the confidence they have from seeing this data,” Allen said.

When asked what the IDWeek conference is like, Allen said, “I typically spend a lot of time at research meetings, and [I] was really excited for the opportunity to [go] and talk to health care providers and listen to how the epidemiology groups and others are talking about different pathogens, of course, and there's a lot of enthusiasm around the work that's been done in the clinic. Take, for example, respiratory syncytial virus (RSV); there have been [several] approvals for RSV vaccines and an antibody for the treatment of that disease. And then that, you know, things like that, where I can hear the epidemiologists and like the people from CDC talk about how policies are being put in place, and then use that as a context to think about where a company like Invyvid could position value in that context, right? And so that's been really interesting for me.”

COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.

(Adobe Stock 333039083 by Production Perig)

To read more IDWeek coverage, read here.